2. Academic Validation
  3. Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone

Agonist antibody to guanylate cyclase receptor NPR1 regulates vascular tone

  • Nature. 2024 Sep;633(8030):654-661. doi: 10.1038/s41586-024-07903-1.
Michael E Dunn 1,  Aaron Kithcart 2,  Jee Hae Kim 2,  Andre Jo-Hao Ho 2,  Matthew C Franklin 2,  Annabel Romero Hernandez 2,  Jan de Hoon 3,  Wouter Botermans 3,  Jonathan Meyer 2,  Ximei Jin 2,  Dongqin Zhang 2,  Justin Torello 2,  Daniel Jasewicz 2,  Vishal Kamat 2,  Elena Garnova 2,  Nina Liu 2,  Michael Rosconi 2,  Hao Pan 2,  Satyajit Karnik 2,  Michael E Burczynski 2,  Wenjun Zheng 2,  Ashique Rafique 2,  Jonas B Nielsen 4,  Tanima De 4,  Niek Verweij 4,  Anita Pandit 4,  Adam Locke 4,  Naga Chalasani 5,  Olle Melander 6 7,  Tae-Hwi Schwantes-An 8,  Penn Medicine Biobank,  Aris Baras 4,  Luca A Lotta 4,  Bret J Musser 2,  Jason Mastaitis 2,  Kishor B Devalaraja-Narashimha 2,  Andrew J Rankin 2,  Tammy Huang 2,  Gary Herman 2,  William Olson 2,  Andrew J Murphy 2,  George D Yancopoulos 2,  Benjamin A Olenchock 2,  Lori Morton 2
Affiliations

Affiliations

  • 1 Regeneron Pharmaceuticals, Tarrytown, NY, USA. [email protected].
  • 2 Regeneron Pharmaceuticals, Tarrytown, NY, USA.
  • 3 Center for Clinical Pharmacology, University Hospitals Leuven, Leuven, Belgium.
  • 4 Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, NY, USA.
  • 5 Indiana University School of Medicine & Indiana University Health, Indianapolis, IN, USA.
  • 6 The Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden.
  • 7 Department of Emergency and Internal Medicine, Skåne University Hospital, Malmö, Sweden.
  • 8 Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
PMID: 39261724 DOI: 10.1038/s41586-024-07903-1
Abstract

Heart failure is a leading cause of morbidity and mortality1,2. Elevated intracardiac pressures and myocyte stretch in heart failure trigger the release of counter-regulatory natriuretic peptides, which act through their receptor (NPR1) to affect vasodilation, diuresis and natriuresis, lowering venous pressures and relieving venous congestion3-8. Recombinant natriuretic peptide infusions were developed to treat heart failure but have been limited by a short duration of effect9,10. Here we report that in a human genetic analysis of over 700,000 individuals, lifelong exposure to coding variants of the NPR1 gene is associated with changes in blood pressure and risk of heart failure. We describe the development of REGN5381, an investigational monoclonal agonist antibody that targets the membrane-bound Guanylate Cyclase receptor NPR1. REGN5381, an allosteric agonist of NPR1, induces an active-like receptor conformation that results in haemodynamic effects preferentially on venous vasculature, including reductions in systolic blood pressure and venous pressure in animal models. In healthy human volunteers, REGN5381 produced the expected haemodynamic effects, reflecting reductions in venous pressures, without obvious changes in diuresis and natriuresis. These data support the development of REGN5381 for long-lasting and selective lowering of venous pressures that drive symptomatology in patients with heart failure.

Figures
Products